Trial Profile

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RSV F protein vaccine-Novavax (Primary)
Indications Respiratory syncytial virus infections
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms Resolve
Sponsors Novavax

Most Recent Events

10 Jan 2017 Status changed from active, no longer recruiting to completed.
15 Sep 2016 Primary endpoint has not been met. (Numbers and percentages of subjects with moderate-severe RSV-LRTD), according to a Novavax Inc. media release.
15 Sep 2016 Results published in the Novavax Inc. Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com